See more : KONE Oyj (KNEBV.HE) Income Statement Analysis – Financial Results
Complete financial analysis of AmerisourceBergen Corporation (ABC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AmerisourceBergen Corporation, a leading company in the Medical – Distribution industry within the Healthcare sector.
- Titanium Transportation Group Inc. (I9V.F) Income Statement Analysis – Financial Results
- The Kyoto Hotel, Ltd. (9723.T) Income Statement Analysis – Financial Results
- Great Quest Fertilizer Ltd. (GQMLF) Income Statement Analysis – Financial Results
- Hyprop Investments Limited (HYP.JO) Income Statement Analysis – Financial Results
- Kiwetinohk Energy Corp. (KEC.TO) Income Statement Analysis – Financial Results
AmerisourceBergen Corporation (ABC)
About AmerisourceBergen Corporation
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 262.17B | 238.59B | 213.99B | 189.89B | 179.59B | 167.94B | 153.14B | 146.85B | 135.96B | 119.57B | 87.96B | 79.49B | 80.22B | 77.95B | 71.76B | 70.19B | 66.07B | 61.20B | 54.58B | 53.18B | 49.66B | 45.23B | 16.19B | 11.65B | 9.81B | 8.67B | 7.82B | 5.55B | 4.67B | 4.30B |
| Cost of Revenue | 253.21B | 230.29B | 207.05B | 184.70B | 174.45B | 163.33B | 148.60B | 142.58B | 132.43B | 116.59B | 85.45B | 76.82B | 77.68B | 75.60B | 69.66B | 68.14B | 63.75B | 58.97B | 52.60B | 51.00B | 47.41B | 43.21B | 15.49B | 11.12B | 9.33B | 8.25B | 7.43B | 5.25B | 4.40B | 4.06B |
| Gross Profit | 8.96B | 8.30B | 6.94B | 5.19B | 5.14B | 4.61B | 4.55B | 4.27B | 3.53B | 2.98B | 2.51B | 2.67B | 2.54B | 2.36B | 2.10B | 2.05B | 2.33B | 2.23B | 1.98B | 2.18B | 2.25B | 2.02B | 700.12M | 520.89M | 475.60M | 423.10M | 389.30M | 304.90M | 268.80M | 243.30M |
| Gross Profit Ratio | 3.42% | 3.48% | 3.24% | 2.73% | 2.86% | 2.75% | 2.97% | 2.91% | 2.60% | 2.49% | 2.85% | 3.36% | 3.17% | 3.02% | 2.93% | 2.92% | 3.52% | 3.65% | 3.63% | 4.10% | 4.53% | 4.48% | 4.32% | 4.47% | 4.85% | 4.88% | 4.98% | 5.49% | 5.76% | 5.66% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -58.48M | 888.84M | 958.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 2.66B | 2.46B | 2.13B | 2.09B | 1.92B | 1.59B | 1.33B | 1.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.32B | 324.14M | 334.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.31B | 4.85B | 3.59B | 2.77B | 2.66B | 2.46B | 2.13B | 2.09B | 1.92B | 1.59B | 1.33B | 1.23B | 1.20B | 1.16B | 1.13B | 1.12B | 1.41B | 1.40B | 1.26B | 1.21B | 1.29B | 1.22B | 408.76M | 303.04M | 281.80M | 254.90M | 255.40M | 195.40M | 160.90M | 150.70M |
| Other Expenses | 1.31B | 693.90M | 505.17M | 391.06M | 462.41M | -25.47M | 2.73M | 5.05M | -13.60M | 4.36M | -44.00K | 5.83M | 0.00 | 0.00 | 1.43B | 1.43B | 1.51B | 1.48B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.62B | 5.54B | 4.10B | 3.16B | 3.13B | 2.93B | 2.53B | 2.46B | 2.16B | 1.77B | 1.50B | 1.37B | 1.33B | 1.25B | 1.20B | 1.21B | 1.50B | 1.48B | 1.34B | 1.29B | 1.36B | 1.28B | 427.63M | 320.46M | 301.70M | 271.50M | 269.70M | 207.00M | 171.00M | 165.40M |
| Cost & Expenses | 259.83B | 235.83B | 211.15B | 187.86B | 177.58B | 166.25B | 151.12B | 145.03B | 134.59B | 118.36B | 86.95B | 78.19B | 79.01B | 76.85B | 70.86B | 69.35B | 65.25B | 60.45B | 53.94B | 52.29B | 48.77B | 44.49B | 15.92B | 11.44B | 9.63B | 8.52B | 7.70B | 5.45B | 4.57B | 4.22B |
| Interest Income | 0.00 | 21.31M | 8.47M | 20.64M | 37.71M | 14.94M | 3.86M | 4.44M | 2.99M | 841.00K | 1.15M | 1.80M | 2.18M | 2.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 228.93M | 210.67M | 182.54M | 137.88M | 157.77M | 174.70M | 145.19M | 139.91M | 99.00M | 76.86M | 73.90M | 95.42M | 78.90M | 72.49M | 58.31M | 32.24M | 32.29M | 12.46M | 0.00 | 0.00 | 0.00 | 140.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 963.90M | 1.11B | 1.05B | 391.06M | 462.41M | 465.13M | 397.60M | 364.74M | 243.28M | 185.29M | 162.19M | 141.05M | 108.31M | 86.46M | 78.91M | 95.88M | 104.34M | 96.93M | 90.88M | 87.09M | 80.44M | 66.58M | 24.71M | 17.42M | 19.90M | 16.60M | 14.30M | 11.60M | 10.10M | 14.70M |
| EBITDA | 3.37B | 3.47B | 3.41B | 2.43B | 2.49B | 2.08B | 2.42B | 2.19B | 1.60B | 1.40B | 1.17B | 1.45B | 1.32B | 1.19B | 974.43M | 950.52M | 931.83M | 841.25M | 843.99M | 994.88M | 967.77M | 833.49M | 307.59M | 216.73M | 208.70M | 194.90M | 133.90M | 109.50M | 107.90M | 272.40M |
| EBITDA Ratio | 1.28% | 1.46% | 1.59% | 1.28% | 1.39% | 1.24% | 1.58% | 1.49% | 1.18% | 1.17% | 1.33% | 1.82% | 1.64% | 1.53% | 1.36% | 1.35% | 1.41% | 1.37% | 1.55% | 1.87% | 1.95% | 1.84% | 1.90% | 1.86% | 2.13% | 2.25% | 1.71% | 1.97% | 2.31% | 6.33% |
| Operating Income | 2.34B | 2.37B | 2.35B | 2.04B | 2.03B | 1.44B | 1.11B | 1.53B | 417.37M | 778.88M | 898.40M | 1.25B | 1.20B | 1.10B | 883.75M | 827.86M | 820.34M | 748.71M | 636.95M | 890.43M | 883.11M | 718.43M | 259.38M | 200.43M | 173.90M | 151.60M | 119.60M | 97.90M | 97.80M | 77.90M |
| Operating Income Ratio | 0.89% | 0.99% | 1.10% | 1.07% | 1.13% | 0.86% | 0.73% | 1.04% | 0.31% | 0.65% | 1.02% | 1.58% | 1.50% | 1.42% | 1.23% | 1.18% | 1.24% | 1.22% | 1.17% | 1.67% | 1.78% | 1.59% | 1.60% | 1.72% | 1.77% | 1.75% | 1.53% | 1.76% | 2.09% | 1.81% |
| Total Other Income/Expenses | -179.90M | -183.32M | -132.34M | -7.33B | -1.06B | -266.26M | -92.46M | -134.86M | -143.22M | -105.46M | -73.94M | -89.60M | -72.10M | -75.87M | -59.68M | -66.52M | -35.29M | -8.08M | -168.12M | -130.06M | -156.98M | -146.38M | -56.54M | -40.73M | -54.60M | -68.80M | -41.60M | -35.90M | -52.30M | -242.50M |
| Income Before Tax | 2.16B | 2.18B | 2.22B | -5.29B | 967.11M | 1.18B | 967.89M | 1.39B | 274.15M | 673.43M | 824.46M | 1.16B | 1.13B | 1.03B | 824.07M | 761.34M | 785.05M | 740.63M | 468.83M | 760.37M | 726.13M | 572.05M | 202.83M | 159.70M | 119.30M | 82.80M | 78.00M | 62.00M | 45.50M | -164.60M |
| Income Before Tax Ratio | 0.82% | 0.91% | 1.04% | -2.79% | 0.54% | 0.70% | 0.63% | 0.95% | 0.20% | 0.56% | 0.94% | 1.46% | 1.41% | 1.32% | 1.15% | 1.08% | 1.19% | 1.21% | 0.86% | 1.43% | 1.46% | 1.26% | 1.25% | 1.37% | 1.22% | 0.96% | 1.00% | 1.12% | 0.97% | -3.83% |
| Income Tax Expense | 428.26M | 516.52M | 677.25M | -1.89B | 112.97M | -438.47M | 553.40M | -37.02M | 409.04M | 389.40M | 331.02M | 454.95M | 424.02M | 391.02M | 312.22M | 292.27M | 291.28M | 272.62M | 176.90M | 291.98M | 284.90M | 227.11M | 77.73M | 60.69M | 48.40M | 32.30M | 30.60M | 19.30M | 17.30M | 7.80M |
| Net Income | 1.75B | 1.70B | 1.54B | -3.40B | 855.37M | 1.66B | 414.48M | 1.43B | -134.89M | 276.48M | 433.71M | 718.99M | 706.62M | 636.75M | 503.40M | 250.56M | 469.17M | 467.71M | 319.20M | 468.39M | 441.23M | 344.94M | 125.10M | 99.01M | 67.50M | 50.50M | 45.40M | 35.50M | 10.20M | -207.70M |
| Net Income Ratio | 0.67% | 0.71% | 0.72% | -1.79% | 0.48% | 0.99% | 0.27% | 0.97% | -0.10% | 0.23% | 0.49% | 0.90% | 0.88% | 0.82% | 0.70% | 0.36% | 0.71% | 0.76% | 0.58% | 0.88% | 0.89% | 0.76% | 0.77% | 0.85% | 0.69% | 0.58% | 0.58% | 0.64% | 0.22% | -4.83% |
| EPS | 8.53 | 8.15 | 7.48 | -16.60 | 4.07 | 7.53 | 1.90 | 6.73 | -0.62 | 1.22 | 1.88 | 2.84 | 2.59 | 2.26 | 1.67 | 0.78 | 1.27 | 1.14 | 0.75 | 1.05 | 1.01 | 0.82 | 0.55 | 0.48 | 0.33 | 0.26 | 0.23 | 0.20 | 0.07 | -5.19 |
| EPS Diluted | 8.53 | 8.04 | 7.39 | -16.60 | 4.04 | 7.53 | 1.87 | 6.32 | -0.62 | 1.17 | 1.84 | 2.80 | 2.54 | 2.22 | 1.66 | 0.77 | 1.25 | 1.13 | 0.74 | 0.99 | 0.95 | 0.77 | 0.50 | 0.48 | 0.33 | 0.25 | 0.23 | 0.19 | 0.07 | -5.19 |
| Weighted Avg Shares Out | 204.59M | 208.47M | 205.92M | 204.78M | 210.17M | 217.87M | 218.38M | 212.21M | 217.79M | 227.37M | 231.07M | 252.91M | 272.47M | 282.26M | 300.57M | 321.28M | 370.36M | 410.02M | 425.26M | 447.35M | 435.38M | 419.74M | 228.74M | 206.21M | 202.79M | 190.71M | 198.35M | 182.05M | 145.71M | 40.00M |
| Weighted Avg Shares Out (Dil) | 204.59M | 211.21M | 208.47M | 204.78M | 211.84M | 220.34M | 221.60M | 225.96M | 217.79M | 235.41M | 235.35M | 256.90M | 277.72M | 287.25M | 302.75M | 324.92M | 375.77M | 414.89M | 431.08M | 471.12M | 463.82M | 448.91M | 251.23M | 208.08M | 206.73M | 202.85M | 200.42M | 184.42M | 145.71M | 40.00M |
AmerisourceBergen Corporation (ABC) Q1 2023 Earnings Call Transcript
AmerisourceBergen (ABC) Surpasses Q1 Earnings and Revenue Estimates
AmerisourceBergen Corp. stock rises on Q1 top line beat, raised guidance
AmerisourceBergen Reports Fiscal 2023 First Quarter Results
AmerisourceBergen Reports Fiscal 2023 First Quarter Results
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
AmerisourceBergen to change name to Cencora later this year
AmerisourceBergen Announces Intent to Change Name to Cencora
AmerisourceBergen Kicks Off Strategic Relationship with Civica
Source: https://incomestatements.info
Category: Stock Reports